| C026486 | 1,2,5,6-dibenzanthracene | "1,2,5,6-dibenzanthracene results in increased expression of CTNND2 mRNA" | 26377693 |
| C030370 | 2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone | "2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in increased expression of CTNND2 mRNA" | 20206263 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C459179 | 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C058722 | 5-hydroxy-6,8,11,14,17-eicosapentaenoic acid | "5-hydroxy-6,8,11,14,17-eicosapentaenoic acid affects the expression of CTNND2 mRNA" | 26984781 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C516138 | (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| D000082 | Acetaminophen | Acetaminophen results in decreased expression of CTNND2 mRNA | 22230336 |
| D016604 | Aflatoxin B1 | Aflatoxin B1 results in decreased methylation of CTNND2 gene | 27153756 |
| D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of CTNND2 mRNA | 16483693 |
| D001280 | Atrazine | Atrazine results in decreased expression of CTNND2 mRNA | 25929836 |
| C547126 | AZM551248 | AZM551248 results in increased expression of CTNND2 mRNA | 22323515 |
| D001564 | Benzo(a)pyrene | Benzo(a)pyrene affects the expression of CTNND2 mRNA | 21714911 |
| D004958 | Estradiol | Estradiol affects the expression of CTNND2 mRNA | 25321415 |
| D004958 | Estradiol | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of CTNND2 mRNA | 19619570 |
| D004958 | Estradiol | Estradiol results in decreased expression of CTNND2 mRNA | 19619570|2118537 |
| D004958 | Estradiol | Estradiol results in increased expression of CTNND2 mRNA | 17555868|2301914 |
| D004958 | Estradiol | [bisphenol A co-treated with Estradiol] results in decreased expression of CTNND2 mRNA | 26496021 |
| C006780 | bisphenol A | [bisphenol A co-treated with Estradiol] results in decreased expression of CTNND2 mRNA | 26496021 |
| C006780 | bisphenol A | bisphenol A results in decreased expression of CTNND2 mRNA | 25181051 |
| C006780 | bisphenol A | bisphenol A results in increased expression of CTNND2 protein | 24552547 |
| C013418 | bromfenacoum | bromfenacoum results in decreased expression of CTNND2 protein | 28903499 |
| D002101 | Cacodylic Acid | Cacodylic Acid results in increased expression of CTNND2 mRNA | 17441966 |
| D002392 | Catechin | [Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of CTNND2 mRNA | 24763279 |
| D020245 | p-Chloromercuribenzoic Acid | "[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| D020245 | p-Chloromercuribenzoic Acid | p-Chloromercuribenzoic Acid results in decreased expression of CTNND2 mRNA | 26272509 |
| D003042 | Cocaine | Cocaine results in decreased expression of CTNND2 mRNA | 12629581 |
| D003042 | Cocaine | Cocaine results in increased expression of CTNND2 mRNA | 16076954 |
| D003375 | Coumestrol | [Coumestrol co-treated with resveratrol] results in decreased expression of CTNND2 mRNA | 19167446 |
| D003375 | Coumestrol | Coumestrol results in decreased expression of CTNND2 mRNA | 19167446 |
| D016578 | Crack Cocaine | Crack Cocaine results in increased expression of CTNND2 mRNA | 12629581 |
| C009160 | cyclonite | cyclonite results in increased expression of CTNND2 mRNA | 25559034 |
| D003520 | Cyclophosphamide | CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | 16896004 |
| D004317 | Doxorubicin | CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | 16896004 |
| C118739 | entinostat | entinostat results in decreased expression of CTNND2 mRNA | 26272509|2718838 |
| C118739 | entinostat | "[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| D005472 | Fluorouracil | CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | 16896004 |
| D004397 | Fonofos | Fonofos results in increased methylation of CTNND2 promoter | 22847954 |
| D019833 | Genistein | Genistein results in increased expression of CTNND2 mRNA | 23019147 |
| C071834 | glycidamide | glycidamide results in decreased expression of CTNND2 mRNA | 17822822 |
| C511402 | Grape Seed Proanthocyanidins | [Catechin co-treated with Grape Seed Proanthocyanidins] results in increased expression of CTNND2 mRNA | 24763279 |
| C042720 | mercuric bromide | mercuric bromide results in decreased expression of CTNND2 mRNA | 26272509 |
| C042720 | mercuric bromide | "[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C004925 | methylmercuric chloride | methylmercuric chloride results in decreased expression of CTNND2 mRNA | 28001369 |
| C406082 | monomethylarsonous acid | monomethylarsonous acid results in increased expression of CTNND2 mRNA | 22108045 |
| D037742 | Nanotubes, Carbon | "Nanotubes, Carbon analog results in decreased expression of CTNND2 mRNA" | 25554681 |
| D037742 | Nanotubes, Carbon | "Nanotubes, Carbon results in decreased expression of CTNND2 mRNA" | 25554681 |
| D009532 | Nickel | Nickel results in decreased expression of CTNND2 mRNA | 24768652|2558310 |
| D017239 | Paclitaxel | CTNND2 mRNA affects the susceptibility to [Paclitaxel co-treated with Fluorouracil co-treated with Doxorubicin co-treated with Cyclophosphamide] | 16896004 |
| C496932 | panobinostat | "[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C496932 | panobinostat | panobinostat results in decreased expression of CTNND2 mRNA | 26272509 |
| D010269 | Paraquat | Paraquat results in decreased expression of CTNND2 mRNA | 21371552 |
| D010278 | Parathion | Parathion results in increased methylation of CTNND2 promoter | 22847954 |
| C076994 | perfluorooctane sulfonic acid | perfluorooctane sulfonic acid results in increased expression of CTNND2 mRNA | 27153767 |
| D010662 | Phenylmercuric Acetate | "[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| D010662 | Phenylmercuric Acetate | Phenylmercuric Acetate results in decreased expression of CTNND2 mRNA | 26272509 |
| D010795 | Phthalic Acids | Phthalic Acids results in decreased expression of CTNND2 mRNA | 21061450 |
| C006253 | pirinixic acid | pirinixic acid results in increased expression of CTNND2 mRNA | 20813756 |
| D011285 | Pregnenolone Carbonitrile | Pregnenolone Carbonitrile results in increased expression of CTNND2 mRNA | 19162173 |
| D011374 | Progesterone | Progesterone results in decreased expression of CTNND2 mRNA | 22238285 |
| C005556 | propionaldehyde | propionaldehyde results in decreased expression of CTNND2 mRNA | 26079696 |
| C059514 | resveratrol | [Coumestrol co-treated with resveratrol] results in decreased expression of CTNND2 mRNA | 19167446 |
| C017947 | sodium arsenite | sodium arsenite affects the methylation of CTNND2 gene | 28589171 |
| D053260 | Soot | Soot results in decreased expression of CTNND2 mRNA | 26551751 |
| C012568 | terbufos | terbufos results in increased methylation of CTNND2 promoter | 22847954 |
| D013749 | Tetrachlorodibenzodioxin | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of CTNND2 mRNA | 19619570 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in decreased expression of CTNND2 mRNA | 19619570 |
| D013749 | Tetrachlorodibenzodioxin | Tetrachlorodibenzodioxin results in increased expression of CTNND2 mRNA | 17555868 |
| C009495 | titanium dioxide | titanium dioxide results in increased expression of CTNND2 mRNA | 23557971 |
| D014118 | Toxins, Biological | "Toxins, Biological affects the expression of CTNND2 mRNA" | 19682533 |
| C012589 | trichostatin A | "[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| C012589 | trichostatin A | trichostatin A results in decreased expression of CTNND2 mRNA | 24935251|2627250 |
| D014415 | Tunicamycin | Tunicamycin results in decreased expression of CTNND2 mRNA | 17127020 |
| D014635 | Valproic Acid | "[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |
| D014635 | Valproic Acid | Valproic Acid affects the expression of CTNND2 mRNA | 25979313 |
| D014635 | Valproic Acid | Valproic Acid results in decreased expression of CTNND2 mRNA | 23179753|2438349 |
| C111237 | vorinostat | "[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CTNND2 mRNA" | 27188386 |